Oculis Holding AG (OCS) Capital Expenditures (2022 - 2026)
Oculis Holding AG (OCS) recorded quarterly Capital Expenditures of -$8939.0 in Q1 2026, up 81.2% quarter-over-quarter from -$47544.5 in Q4 2025, and up 38.18% on a YoY basis from -$6469.2 in Q1 2025.
Oculis Holding AG (OCS) Capital Expenditures (2022 - 2026) Analysis & Trends
Oculis Holding AG's Capital Expenditures history runs 5 years deep, the most recent figure standing at -$8939.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 38.18% year-over-year to -$8939.0; the TTM figure through Mar 2026 stood at -$363691.2 (down 38.33% YoY), while the FY2025 annual figure was -$376602.1, down 43.44% from the prior year.
- Capital Expenditures was -$8939.0 for Q1 2026 at Oculis Holding AG, up from -$47544.5 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of -$5636.8 in Q4 2023 to a low of -$177747.9 in Q3 2024.
- Historically, Capital Expenditures has averaged -$63064.4 across 5 years, with a median of -$31063.7 in 2022.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures soared 61.21% in 2023, then plunged 1054.33% in 2024.
- A 5-year view of Capital Expenditures shows it stood at -$14532.3 in 2022, then jumped by 61.21% to -$5636.8 in 2023, then slumped by 1054.33% to -$65066.7 in 2024, then climbed by 26.93% to -$47544.5 in 2025, then surged by 81.2% to -$8939.0 in 2026.
- The last three Capital Expenditures figures came in at -$8939.0 (Q1 2026), -$47544.5 (Q4 2025), and -$155013.6 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 860,679.92 Bn | 860,679.89 Bn | - | - |
| 2 | Belite Bio | 55,284.00 Bn | 55,284.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,206.94 Bn | 16,206.93 Bn | - | - |
| 4 | Legend Biotech | 3,318.00 Bn | 3,317.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,543.84 Bn | 1,543.84 Bn | - | - |
| 6 | Evaxion A | 1,449.11 Bn | 1,449.09 Bn | - | - |
| 7 | Psyence Biomedical | 216.99 Bn | 216.98 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 115.22 Bn | 107.97 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 90.58 Bn | 90.58 Bn | - | -63,220.27 |
| 10 | Oculis Holding AG | 8.45 Bn | 8.15 Bn | - | -8,939.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,939.03 |
| Mar 31, 2026 | -8,939.03 |
| Dec 31, 2025 | -47,544.45 |
| Dec 31, 2025 | -47,544.45 |
| Sep 30, 2025 | -155,013.58 |
| Sep 30, 2025 | -155,013.58 |
| Jun 30, 2025 | -152,194.17 |
| Jun 30, 2025 | -152,194.17 |
| Mar 31, 2025 | -14,459.26 |
| Mar 31, 2025 | -14,459.26 |
| Dec 31, 2024 | -65,066.75 |
| Dec 31, 2024 | -65,066.75 |
| Sep 30, 2024 | -177,747.92 |
| Sep 30, 2024 | -177,747.92 |
| Dec 31, 2023 | -5,636.77 |
| Dec 31, 2023 | -5,636.77 |
| Sep 30, 2023 | -21,510.90 |
| Sep 30, 2023 | -21,510.90 |
| Dec 31, 2022 | -14,532.31 |
| Dec 31, 2022 | -14,532.31 |